3 completed, 1 active not recruiting, 1 terminated, 1 unknown. 6 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 3, Active not recruiting 1, Terminated 1, Unknown 1 |
| Phase 3 | 3 | Completed 2, Unknown 1 |
Follow Hepatomegaly: new trials by email Literature Review of Hepatomegaly trials Research Report on Hepatomegaly
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders Ruxolitinib - BCR-JAK2 Fusion Protein Expression, Blasts 20 Percent or Less of Peripheral Blood White Cells | Phase 2 | Active not recruiting | Stanford University | 8 | 2019-11-15 | 2026-09-01 |
| S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis Isatuximab, Laboratory Biomarker Analysis - Amorphous, Eosinophilic, and Acellular Deposit, Constipation | Phase 2 | Completed | SWOG Cancer Research Network | 43 | 2018-06-06 | 2025-09-09 |
| Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis Laboratory Biomarker Analysis, Nivolumab, Quality-of-Life Assessment - Hepatomegaly, Myelofibrosis Transformation in Essential Thrombocythemia | Phase 2 | Terminated | M.D. Anderson Cancer Center | 8 | 2015-05-14 | 2019-05-15 |
| Open-Label Extension of LOCKCYST Trial lanreotide - Polycystic Liver Disease, Hepatomegaly | Phase 2 / Phase 3 | Unknown | Radboud University Medical Center | 54 | 2008-04-01 | 2008-11-13 |
| Lanreotide as Treatment of Polycystic Livers Placebo, Lanreotide - Polycystic Liver Disease, Hepatomegaly | Phase 2 / Phase 3 | Completed | Radboud University Medical Center | 38 | 2007-10-01 | 2009-02-17 |
| Octreotide in Severe Polycystic Liver Disease Octreotide, Placebo - Polycystic Kidney, Autosomal Dominant, Polycystic Liver Disease | Phase 2 / Phase 3 | Completed | Mayo Clinic | 42 | 2007-01-01 | 2012-11-21 |
Liver Diseases (3) · Polycystic liver disease (3) · Polycystic Kidney Diseases (2) · Polycystic Kidney, Autosomal Dominant (2) · Splenomegaly (2) · Abdominal Pain (1) · Constipation (1) · Diarrhea (1) · Eosinophilia (1) · Gastrointestinal Hemorrhage (1) · Hypereosinophilic Syndrome (1) · Immunoglobulin Light-chain Amyloidosis (1) · Lymphadenopathy (1) · Macroglossia (1)
Digestive System Diseases (6) · Hypertrophy (6) · Pathological Conditions, Anatomical (6) · Pathological Conditions, Signs and Symptoms (6) · Abnormalities, Multiple (3) · Ciliopathies (3) · Congenital Abnormalities (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3) · Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Genetic Diseases, Inborn (3) · Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3) · Kidney Diseases (3) · Kidney Diseases, Cystic (3)
lanreotide (2) · Nivolumab (1) · Octreotide (1) · isatuximab (1) · ruxolitinib (1)
Radboud University Medical Center (2) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · SWOG Cancer Research Network (1) · Stanford University (1)
United States (4) · Belgium (2) · Netherlands (2)
Frederik Nevens, MD, PhD (2) · Loes van Keimpema, MSc (2) · Emma Scott (1) · Joost PH Drenth, MD, PhD (1) · Joost PH Drenth, PhD (1) · Marie C. Hogan, M.D., Ph.D. (1) · Srdan Verstovsek (1) · William E Shomali, MD (1)
PMID 39356039, PMID 22773240, PMID 26166166, PMID 40925099
P30CA016672 (1), U10CA180888 (1), UL1RR024150 (1)